1320 related articles for article (PubMed ID: 27076371)
1. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
Teachey DT; Lacey SF; Shaw PA; Melenhorst JJ; Maude SL; Frey N; Pequignot E; Gonzalez VE; Chen F; Finklestein J; Barrett DM; Weiss SL; Fitzgerald JC; Berg RA; Aplenc R; Callahan C; Rheingold SR; Zheng Z; Rose-John S; White JC; Nazimuddin F; Wertheim G; Levine BL; June CH; Porter DL; Grupp SA
Cancer Discov; 2016 Jun; 6(6):664-79. PubMed ID: 27076371
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
[TBL] [Abstract][Full Text] [Related]
6. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
[TBL] [Abstract][Full Text] [Related]
7. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
9. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
[TBL] [Abstract][Full Text] [Related]
10. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
11. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Gardner RA; Ceppi F; Rivers J; Annesley C; Summers C; Taraseviciute A; Gust J; Leger KJ; Tarlock K; Cooper TM; Finney OC; Brakke H; Li DH; Park JR; Jensen MC
Blood; 2019 Dec; 134(24):2149-2158. PubMed ID: 31697826
[TBL] [Abstract][Full Text] [Related]
12. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
13. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
14. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
15. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S; Myers RM; Li Y; Aplenc R; Baniewicz D; Barrett DM; Barz Leahy A; Callahan C; Dolan JG; Fitzgerald JC; Gladney W; Lacey SF; Liu H; Maude SL; McGuire R; Motley LS; Teachey DT; Wertheim GB; Wray L; DiNofia AM; Grupp SA
J Clin Oncol; 2021 Mar; 39(8):920-930. PubMed ID: 33417474
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
17. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia.
Heng G; Jia J; Li S; Fu G; Wang M; Qin D; Li Y; Pei L; Tian X; Zhang J; Wu Y; Xiang S; Wan J; Zhu W; Zhang P; Zhang Q; Peng X; Wang L; Wang P; Wei Z; Zhang Y; Wang G; Chen X; Zhang C; Sun Y; Zhao W; Fan Y; Yang Z; Chen J; Qian C
Clin Cancer Res; 2020 Apr; 26(7):1606-1615. PubMed ID: 31732519
[TBL] [Abstract][Full Text] [Related]
18. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Fitzgerald JC; Weiss SL; Maude SL; Barrett DM; Lacey SF; Melenhorst JJ; Shaw P; Berg RA; June CH; Porter DL; Frey NV; Grupp SA; Teachey DT
Crit Care Med; 2017 Feb; 45(2):e124-e131. PubMed ID: 27632680
[TBL] [Abstract][Full Text] [Related]
19. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Mueller KT; Maude SL; Porter DL; Frey N; Wood P; Han X; Waldron E; Chakraborty A; Awasthi R; Levine BL; Melenhorst JJ; Grupp SA; June CH; Lacey SF
Blood; 2017 Nov; 130(21):2317-2325. PubMed ID: 28935694
[TBL] [Abstract][Full Text] [Related]
20. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
